vimarsana.com

Page 10 - அல்ஜெர்னான் மருந்துகள் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FTSE 100 slips into the red at the close as Wall Street struggles

The London stock market somewhat mirrored London’s weather today; a pleasant start, followed by heavy showers and then a traditional British tepid finish.

NA Proactive news snapshot: First Cobalt Corp, GlobeX Data Ltd, Loop Insights Inc, Else Nutrition Holdings Inc, Victory Square Technologies Inc, Jack Nathan Medical Corp, Gold Resource Corporation, Metalla Royalty & Streaming Ltd, OTC Markets Group Inc, A

NA Proactive news snapshot: BioHarvest Sciences Inc , Marble Financial Inc, ElectraMeccanica Vehicles Corp, Ion Energy Ltd UPDATE …

NA Proactive news snapshot: BioHarvest Sciences, Marble Financial, ElectraMeccanica Vehicles, Ion Energy UPDATE … A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive BioHarvest Sciences Inc. (CSE:BHSC) (FRA:8MV) has announced the launch of direct-to-consumer sales of its flagship product VINIA in the United States, via its vinia.com website. After years of developing its BioFarming technology, the company said it is proud to bring the first product based on this technology to the US market. VINIA is the first and only product in the world containing Piceid Resveratrol from red grapes at levels in each 400mg capsule of VINIA equivalent to an average bottle of red wine, providing the benefits of red wine with the advantage of zero calories, zero sugar and zero percent alcohol. BioHarvest said the successful launch of VINIA in Israel has provided the company with experience in

Algernon Pharmaceuticals Inc reports findings from Ifenprodil Phase 2b/3 coronavirus trial may be positive for idiopathic pulmonary fibrosis (IPF) and chronic cough study

In a mouse model, blockade of IL-6 has been shown to attenuate (reduce) pulmonary fibrosis. On May 11, 2021, the company announced that it had reached 50% of its enrollment target for its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its repurposed drug NP-120 (Ifenprodil). The 20 patient proof-of-concept trial is designed to determine the efficacy of Ifenprodil in the preservation of lung function in patients suffering from IPF and its associated chronic cough. There are six sites participating in the study, with four located in Australia and two in New Zealand. Ifenprodil has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine (mouse) model of IPF, the company said, and it significantly reduced cough frequency and delayed onset in a guinea pig acute cough model.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.